Drug Survival on First Biologic Therapy Among Late‐Onset Rheumatoid Arthritis Patients Compared to Early‐Onset Patients: A Population‐Based Cohort Study
Musculoskeletal Care · 2024
DOI: 10.1002/msc.1928 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Musculoskeletal Care, 2024. Verfasst von Helana Jeries und 7 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Unit, Galilee Medical Center, Nahariya, Israel. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents, Age of Onset, Biological Products. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction
Rheumatoid arthritis (RA) patients can be divided according to the age of disease onset and classified as late‐onset RA ≥ 60 years old or early‐onset RA < 60 years old. Current treatment guidelines do not stipulate any preference regarding the biologic that should be used first in the late‐onset group. This study aims to compare the drug survival times on first biological treatment between late and early‐onset RA patients.
Methods
This is a population based cohort study using the medical records of Leumit healthcare services. We included all eligible RA patients between 2000 and 2017. RA patients were divided into late‐ and early‐onset RA groups and compared according to drug survival time on the first biological therapy.
Results
The final cohort included 3814 RA patients, 2807 (73.6%) of whom had early‐onset RA. Overall, biologic disease‐modifying anti‐rheumatic drugs (bDMARDs) were used more often among early‐onset compared to late‐onset patients (16.9% vs. 7.8%, p < 0.001). Among early‐onset patients, etanercept was associated with the longest drug survival time on the first biologic, and adalimumab and infliximab were associated with the longest drug survival times among late‐onset patients. No differences were observed in drug survival times between late and early‐onset patients on the first bDMARD, except for abatacept and golimumab with longer drug survival time among early‐onset patients.
Conclusion
Late‐onset RA patients were treated with biologics to a lesser extent than early‐onset patients, but no differences were observed in drug survival times at the first bDMARD between the two groups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Rheumatology Unit, Galilee Medical Center, Nahariya, Israel.
- Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
- Medical Division, Leumit Healthcare Services, Tel Aviv-Yaffo, Israel.
- Faculty of Medicine, Tel Aviv University, Tel Aviv-Yaffo, Israel.
ORCID-Profile: Mohammad E Naffaa, Fadi Hassan
Zitieren
APA
Jeries, H., Daood, R., Hijazi, B., Golan-Cohen, A., Green, I., Merzon, E., Naffaa, M. E., & Hassan, F. (2024). Drug Survival on First Biologic Therapy Among Late‐Onset Rheumatoid Arthritis Patients Compared to Early‐Onset Patients: A Population‐Based Cohort Study. Musculoskeletal Care. https://doi.org/10.1002/msc.1928
Vancouver
Jeries H, Daood R, Hijazi B, Golan-Cohen A, Green I, Merzon E, et al. Drug Survival on First Biologic Therapy Among Late‐Onset Rheumatoid Arthritis Patients Compared to Early‐Onset Patients: A Population‐Based Cohort Study. Musculoskeletal Care. 2024. doi:10.1002/msc.1928
BibTeX
@article{Jeries2024,
author = {Jeries, Helana and Daood, Rula and Hijazi, Basem and Golan-Cohen, Avivit and Green, Ilan and Merzon, Eugene and Naffaa, Mohammad E and Hassan, Fadi},
title = {Drug Survival on First Biologic Therapy Among Late‐Onset Rheumatoid Arthritis Patients Compared to Early‐Onset Patients: A Population‐Based Cohort Study},
journal = {Musculoskeletal Care},
year = {2024},
doi = {10.1002/msc.1928}
}
EUVIMED